Book contents
- Commercializing Successful Biomedical Technologies
- Commercializing Successful Biomedical Technologies
- Copyright page
- Dedication
- Contents
- Preface
- Acknowledgments
- 1 The biomedical device and drug industry and their markets
- 2 Markets of interest and market research steps
- 3 Starting up your company
- 4 Intellectual property and licensing
- 5 New product development (NPD)
- 6 The regulated market: gateway through the FDA
- 7 Manufacturing
- 8 Reimbursement, marketing, sales, and product liability
- Glossary
- Index
- References
1 - The biomedical device and drug industry and their markets
Published online by Cambridge University Press: 03 November 2022
Book contents
- Commercializing Successful Biomedical Technologies
- Commercializing Successful Biomedical Technologies
- Copyright page
- Dedication
- Contents
- Preface
- Acknowledgments
- 1 The biomedical device and drug industry and their markets
- 2 Markets of interest and market research steps
- 3 Starting up your company
- 4 Intellectual property and licensing
- 5 New product development (NPD)
- 6 The regulated market: gateway through the FDA
- 7 Manufacturing
- 8 Reimbursement, marketing, sales, and product liability
- Glossary
- Index
- References
Summary
The vast world of biotechnology applications to human health is reviewed and the terminology used in the rest of the book is defined here. An overview of the industry, the value chains, the specific types of human health products covered in this text are presented in this chapter. A time-tested way to analyze an industry’s attractiveness for new entrants is presented here using Porter’s five forces model. Technology trends such as mobile health, artificial intelligence, 3D printing, cell and gene therapy, and robotics are presented to the reader in the context of the mission of improving human health. The overall process of development of new products in these various segments of drugs, devices and diagnostics sectors is reviewed here. The reader will leave this chapter with a 30,000-foot view of the industry dynamics and understand the context within which product commercialization is to be done.
Keywords
- Type
- Chapter
- Information
- Commercializing Successful Biomedical Technologies , pp. 1 - 41Publisher: Cambridge University PressPrint publication year: 2022
References
References and additional readings
Burns, L. (editor). (2002). The Health Care Value Chain. San Francisco: Jossey-Bass. ISBN: 0787960217Google Scholar
Cheng, C-M, Kuan, C-M, and Chen, C-F. (2015). In-Vitro Diagnostic Devices: Introduction to Current Point-of-Care Diagnostic Devices. Springer International Publishing. ISBN: 9783319197371Google Scholar
Chiesa, V, and Chiaroni, D. (2004). Industrial Clusters in Biotechnology. Imperial College Press. ISBN:1860944981Google Scholar
Collins, SW. (2004). The Race to Commercialize Biotechnology. London: Routledge Press. ISBN: 0415283396.Google Scholar
DiMasi, JA, Grabowski, HG, and Hansen, RW. (2016, May). Innovation in the pharmaceutical industry: new estimates of R&D costs, Journal of Health Economics, 47, 20–33.CrossRefGoogle ScholarPubMed
Ecker, DM, Jones, SD, and Levine, HL. (2015). The therapeutic monoclonal antibody market. mAbs 7(1), 9–14.Google Scholar
Ernst & Young Annual Biotechnology Industry Reports. (2015–2020). Ernst & Young LLP.Google Scholar
Evaluate Biotech and Medtech 2020 in review. (2021). www.evaluate.com/thought-leadership/vantage/evaluate-vantage-pharma-biotech-medtech-2020-reviewGoogle Scholar
Fortune Business Insights Report. (2021). The global monoclonal antibody therapy market 2021–2028. Report ID FBI102734. www.fortunebusinessinsights.com/monoclonal-antibody-therapy-market-102734Google Scholar
Frost and Sullivan. (2022b). Global in vitro diagnostics market outlook (SKU: HC03451-NA-MT_25793).Google Scholar
Kayser, O, and Müller, R. (editors). (2004). Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications. New York: John Wiley & Sons. ISBN: 3527305548Google Scholar
Lu, RM, Hwang, YC, Liu, IJ, et al. (2020). Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science 27(1), 1. https://doi.org/10.1186/s12929-019-0592-zGoogle Scholar
McKelvey, MD, Rickne, A, and Laage-Hellman, J. (editors). (2004). The Economic Dynamics of Modern Biotechnology. Edward Elgar Publishing. ISBN 1843765195Google Scholar
Ono, R. (2013). Business of Biotechnology: From the Bench to the Street. Elsevier Science. ISBN: 9781483292236Google Scholar
Porter, M. (1985). Competitive Advantage: Creating and Sustaining Superior Performance. New York: The Free Press. ISBN: 0684841460Google Scholar
Roco, MC, and Bainbridge, WS. (editors). (2004). Converging Technologies for Improving Human Performance. Springer. ISBN: 1402012543Google Scholar
Saltzman, M. (2015). Biomedical Engineering: Bridging Medicine and Technology. Cambridge: Cambridge University Press, 2nd ed. ISBN: 9781107037199Google Scholar
Shimasaki, C. (2014). Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies. Elsevier Science. ISBN: 9780124047471.CrossRefGoogle Scholar
Springham, DG, Cape, RE, and Moses, V. (editors). (2020). Biotechnology – The Science and the Business. Boca Raton, FL: CRC Press. ISBN: 9781000159660Google Scholar
Srinivasan, P, Shanmugam, T, Chokkalingam, L, and Bakthavachalam, P. (editors). (2020). Trends in Development of Medical Devices. Elsevier Science. ISBN: 0128209615Google Scholar